Literature DB >> 1779485

Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes.

M Sakurai1, M Araie, T Oshika, M Mori, K Masuda, R Ueno, M Takase.   

Abstract

The mechanism underlying the intraocular pressure (IOP) lowering effect of a prostaglandin-related compound, isopropyl 20-ethyl-9 alpha,11 alpha-dihydroxy-15-keto-cis-delta 5-prostanoate (UF-021), and its possible adverse effects in long-term use were studied in normal human eyes. A single instillation of 0.12% UF-021 significantly lowered IOP without affecting aqueous flow rate, tonographic C value or episcleral venous pressure. Protein concentration in the anterior chamber and corneal endothelial permeability to fluorescein remained unaffected. It was suggested that UF-021 lowers IOP mainly by increasing uveoscleral outflow. Twice daily application of 0.12% UF-021 for 4 weeks caused no significant changes in aqueous protein concentration, aqueous flow rate or corneal endothelial permeability. Neither single nor long-term use of topical UF-021 induced irritative responses in the outer segment of the eye. The present study suggests that UF-021 has potential as a safe and effective ocular hypotensive drug with a mechanism of action different from other drugs currently available for the treatment of glaucoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1779485

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  13 in total

1.  Regeneration of optic nerve fibers with unoprostone, a prostaglandin-related antiglaucoma drug, in adult cats.

Authors:  Hiroe Sagawa; Hiroko Terasaki; Keiko Nakanishi; Yoshihito Tokita; Masami Watanabe
Journal:  Jpn J Ophthalmol       Date:  2013-10-16       Impact factor: 2.447

Review 2.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

3.  Additional reduction in intraocular pressure achieved with latanoprost in normal-tension glaucoma patients previously treated with unoprostone.

Authors:  Miho Enoki; Jun Saito; Makiko Hara; Tetsuya Uchida; Takeshi Sagara; Teruo Nishida
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

Review 4.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans.

Authors:  M Kanno; M Araie; H Koibuchi; K Masuda
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

Review 6.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  S S Patel; C M Spencer
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

7.  Unoprostone (isopropyl unoprostone)

Authors:  M Haria; C M Spencer
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 8.  A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension.

Authors:  D L Eisenberg; C B Camras
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

9.  The Water-Drinking Test Revisited: An Analysis of Test Results in Subjects with Glaucoma.

Authors:  M Reza Razeghinejad; Zahra Tajbakhsh; M Hossein Nowroozzadeh; Shane J Havens; Deepta Ghate; Vikas Gulati
Journal:  Semin Ophthalmol       Date:  2017-05-24       Impact factor: 1.975

10.  Physicochemical and biological characterization of sustained isopropyl unoprostone-release device made of poly(ethyleneglycol) dimethacrylates.

Authors:  Nobuhiro Nagai; Yasuko Izumida; Yoshimasa Yamazaki; Hirokazu Kaji; Junichi Kawasaki; Matsuhiko Nishizawa; Toshiaki Abe
Journal:  J Mater Sci Mater Med       Date:  2017-05-22       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.